COVID-19 pandemic and initiation of treatment for atrial fibrillation: a nationwide analysis of claims data

Table 2 Results of Interrupted Time Series Analysis

Initiation of outcomes within 30 days of AF diagnosis	Level Change(95%CI), per 1000 patients^a	P-Value	Trend Change(95% CI), per 1000 patients ^b	P-Value
Primary Outcome
Oral anticoagulation	3.2(-8.5,14.9)	0.59	1.0(-0.9,1.1)	0.85
Secondary Outcomes
Warfarin	7.6(2.2,12.9)	< 0.01	1.1(0.6,1.6)	< 0.01
DOAC	-4.4(-16.7,8.0)	0.49	-1.0(-2.1,0.1)	0.07
Rhythm control medications	-1.1(-2.8,0.6)	0.20	0.1(0.0,0.3)	0.14
Electrical cardioversion	-4.9(-9.3,-0.6)	0.02	0.1(-0.2,0.5)	0.45

Abbreviations: DOAC, direct oral anticoagulant
a The level change represents the abrupt change in the outcome immediately after the onset of the COVID-19 pandemic and is given by the indicator variable for the period after 3/11/2020
b The trend change represents the change in the slope of the outcome after the onset of the COVID-19 pandemic and is given by the interaction between the continuous variable for time and the indicator variable for the period after 3/11/2020

ISSN: 1471-2261